Session information
- Title:
- In vivo gene therapy
- Description:
-
This session explains the concepts underpinning a form of advanced therapy medicinal product (ATMP) known as in vivo (lit. in life) gene therapies. It describes their governance and the risks and requirements inherent in their safe handling and delivery. Examples are provided of in vivo gene therapies and highly related therapies which are already approved in the UK or expected to be approved in the near future.
- Hierarchy:
- Advanced Therapy Medicinal Products (ATMP) > Advanced Therapy Medicinal Products > In vivo gene therapy
- Created:
- 8 Jul 2021
- Last Major Update:
- 8 Jul 2021
- Keywords:
- 830-0003, Advanced, Medicinal, Products, ATMP, In vivo, Gene therapy, Luxturna, Imlygic, Spinraza, Haemophilia, Zolgensma, AAV, GMO, melanoma
- Quicklink:
- 830-0003
Share this item
- Copy URL
Overall rating
4.6/5
4.6/5
Content
4.7/5
4.7/5
Presentation
4.6/5
4.6/5
Interactivity
4.5/5
4.5/5
Self assessments
4.5/5
4.5/5
Overall rating
4.6/5
4.6/5
Content
4.7/5
4.7/5
Presentation
4.6/5
4.6/5
Interactivity
4.5/5
4.5/5
Self assessments
4.5/5
4.5/5
- Title:
- In vivo gene therapy
- Description:
-
This session explains the concepts underpinning a form of advanced therapy medicinal product (ATMP) known as in vivo (lit. in life) gene therapies. It describes their governance and the risks and requirements inherent in their safe handling and delivery. Examples are provided of in vivo gene therapies and highly related therapies which are already approved in the UK or expected to be approved in the near future.
- Hierarchy:
- Advanced Therapy Medicinal Products (ATMP) > Advanced Therapy Medicinal Products > In vivo gene therapy
- Created:
- 8 Jul 2021
- Last Major Update:
- 8 Jul 2021
- Keywords:
- 830-0003, Advanced, Medicinal, Products, ATMP, In vivo, Gene therapy, Luxturna, Imlygic, Spinraza, Haemophilia, Zolgensma, AAV, GMO, melanoma
- Quicklink:
- 830-0003